CTOs on the Move

Rhythm Pharmaceuticals

www.rhythmtx.com

 
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.rhythmtx.com
  • 222 Berkeley Street 12th Floor
    Boston, MA USA 02116
  • Phone: 857.264.4280

Executives

Name Title Contact Details
Taylor Cucchiara
Associate Director, Cybersecurity Profile

Funding

Rhythm Pharmaceuticals raised $41M on 02/17/2017
Rhythm Pharmaceuticals raised $37.5M on 06/16/2022

Similar Companies

Alios BioPharma

Alios BioPharma is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BiomedAIliance

BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transcriptic

Transcriptic is a very small company. We like it that way. Our work culture is an unstructured environment where you can do your best work supported by a group of your peers. Everyone sets their own goals, and everyone is empowered to think creatively. We work hard and we focus, but we don`t do all-nighters or heroic pushes. Grinding yourself into the ground is a fast way to introduce bugs. Life science demands precision; we take our time and we get it right. We use commercial-off-the-shelf solutions when they`re available, and we aren`t afraid to open them up to get to more exacting standards—and if we can`t find it, we build it. We`re completely devoted to solving Transcriptic`s challenges as cleverly as possible to build solid, reliable, intelligent solutions.

Lucigen

Located in Middleton, WI, Lucigen delivers innovative products and services to life scientists and manufacturers for the most pressing challenges in research and molecular diagnostics. With a focus on quality, ease-of-use, and affordability, Lucigen strives to make our customer’s research, manufacturing and diagnostic testing successful and cost-efficient.

Reverie Labs

Engineering next‑generation, brain‑penetrant cancer therapies.